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Abstract
The regulation of tissue transglutaminase (TG2) activity by the GPCR family is poorly understood. In this study, we investigated the modulation of TG2 activity by the A1 adenosine receptor in cardiomyocyte-like H9c2 cells.H9c2 cells were lysed following stimulation with the A1 adenosine receptor agonist N 6 -cyclopentyladenosine (CPA).
Transglutaminase activity was determined using an amine incorporating and a protein cross linking assay. TG2 phosphorylation was assessed via immunoprecipitation and . CPA triggered robust increases in the levels of TG2-associated phosphoserine and phosphothreonine, which were attenuated by PKC, MEK1/2 and JNK1/2 inhibitors. Fluorescence microscopy revealed TG2-mediated biotin-X-cadaverine incorporation into proteins and proteomic analysis identified known (Histone H4) and novel (Hexokinase 1) protein substrates for TG2. CPA pre-treatment reversed hypoxia-induced LDH release and decreases in MTT reduction. TG2 inhibitors R283 and Z-DON attenuated A1 adenosine receptor-induced cytoprotection. TG2 activity was stimulated by the A1 adenosine receptor in H9c2 cells via a multi protein kinase dependent pathway. These results suggest a role for TG2 in A1 adenosine receptorinduced cytoprotection.
Introduction
Transglutaminases (TGs) comprise a family of calcium (Ca 2+ ) dependent enzymes (TG1-7 and Factor XIIIa) that catalyse post-translational modification of proteins. Once Ca 2+ binds to TG, a cysteine is exposed leading to the formation of a bond between ε-amide (as an isodipeptide or polyamine bond) and γ-carboxamide of protein bound glutamine residues [1] . Transglutaminase 2 (TG2), the most widely studied member of the TG family, has been implicated in the regulation of a wide range of processes, including cell adhesion, migration, growth, survival, apoptosis, differentiation, and extracellular matrix organization [2] . The role of TG2 in cell survival and cell death is cell-specific with respect to whether it has pro-or anti-apoptotic effects [3] . Dysregulation of TG2 occurs in many pathologies, including coeliac disease, neurodegenerative disorders, some cancers and, as such, represents a potential therapeutic target [4] .
Transglutaminase 2 possesses multiple enzymic functions that include transmidation, protein disulphide isomerase and protein kinase activity [5] . The transamidase activity of TG2 is inhibited by GTP/GDP and when bound to GTP/GDP, TG2 functions as a G-protein known as Gh independently of its transamidase activity [6] . Interestingly, the activity of TG2 and other TGs can be regulated by protein kinases. For example, phosphorylation of TG2 by protein kinase A (PKA) inhibits its transamidating activity but enhances its kinase activity [7] , whereas cross-linking activity of TG1 is enhanced by phorbol ester-induced modulates TG2 phosphorylation and activity via a multi protein kinase and extracellular Ca 2+ -dependent pathway. air/5% CO2 at 37°C) until 70-80% confluent and sub-cultured (1:5 split ratio) using trypsin (0.05% w/v)/EDTA (0.02% w/v). Experiments were performed on passage numbers 2-28.
Materials and methods

Materials
BAPTA
Transglutaminase activity assays
Time course profiles and concentration-response response curves were obtained for CPA and adenosine. Where appropriate, cells were also pre-incubated for 30 min in medium with or without the protein kinase inhibitors Ro 31-8220 (PKC; 10 µM; [20] protease inhibitor cocktail, and 1% (v/v) phosphatase inhibitor cocktail 2). Cell lysates were clarified by centrifugation at 4°C for 10 min at 14000 x g prior to being assayed for TG2 activity, as described below. Protein was determined using the bicinchoninic acid (BCA) protein assay [24] , using a commercially available kit (Sigma-Aldrich Co. Ltd),
with bovine serum albumin (BSA) as the standard Biotin-labeled cadaverine-incorporation assays were performed according to Slaughter et al. [25] with modifications [26] , as described previously [27] . The biotin-labeled peptide cross-linking assay was performed according to the method of Trigwell et al. [28] with minor modifications [27] . The reaction was started by the addition of 50 μl of samples, positive control (50 ng/well of guinea-pig liver TG2) or negative control (100 mM TrisHCl, pH 8.0) and allowed to proceed for 1 h at 37°C. In both assays, the reaction was terminated by adding 50 μl of 5.0 M sulphuric acid and the absorbance read at 450 nm.
One unit of TG2 was defined as a change in absorbance of one unit h -1 .
Hypoxia-induced cell death
H9c2 cells in glucose-free and serum-free DMEM (Gibco™, Life Technologies Ltd, Paisley, UK) were exposed to 8 h hypoxia using a hypoxic incubator (5% CO2/1% O2 at 37°C) in which O2 was replaced by N2.
Cell viability assays
H9c2 cells were plated in 24-well flat bottomed plates (15,000 cells per well) and cultured for 24 h in fully supplemented DMEM, before cell viability was determined by measuring the reduction of MTT [29] . The amount of DMSO-solubilised reduced formazan product was determined by measurement of absorbance at a wavelength 570 nm. Alternatively, cells
were plated in 96-well flat bottomed plates (5,000 cells per well) and incubated as above.
Following normoxia/hypoxia exposure, the activity of lactate dehydrogenase (LDH) released into the culture medium was detected using the CytoTox 96 ® non-radioactive cytotoxicity assay (Promega, Southampton, UK) with measurement of absorbance at 490 nm.
SDS-polyacrylamide gel electrophoresis and Western blot analysis
Protein samples (15-20 μg) were separated by SDS-PAGE in 10% (w/v) polyacrylamide gels using a Bio-Rad Mini-Protean III system. Proteins were transferred to nitrocellulose membranes in a Bio-Rad Trans-Blot system, using electro-transfer buffer comprising 25 mM Tris, 192 mM glycine pH 8.3 and 20% (v/v) MeOH. Following transfer, the membranes were blocked and probed with antibodies as described by Alamami et al. [27] . The primary antibodies (1:500 dilutions unless otherwise indicated) used were phospho-specific ERK1/2 (1:1000), phospho-specific PKB, phospho-specific p38 MAPK, phospho-specific JNK. Horseradish peroxidase-conjugated secondary antibodies (New England Biolabs (UK) Ltd), diluted 1:1000 in blocking buffer, were applied for 2h at room temperature. Following removal of the unbound secondary antibody, blots were extensively washed and developed using the Enhanced Chemiluminescence (ECL)
Detection System (Uptima, Interchim, France) and quantified by densitometry using Advanced Image Data Analysis Software (Fuji; version 3.52). Samples were also analysed using primary antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK
(1:1000) in order to confirm the uniformity of protein loading.
Measurement of in situ TG2 activity
H9c2 cells were seeded on 8-well chamber slides (15,000 cells well with a 20x air objective. Optical sections were typically 1-2 µm and the highest fluorescence intensity was acquired using forskolin (10 µM) as a positive control [27] .
Image analysis and quantification were carried out using Leica LAS AF software. 
Measurement of intracellular calcium
Determination of TG2 phosphorylation
Following stimulation, H9c2 cells were rinsed twice with 2.0 ml of chilled PBS and lysed with 500 μl of ice-cold lysis buffer (2mM EDTA, 1. resolved by SDS-PAGE and Western blotting, then probed using anti-phosphoserine or anti-phosphothreonine antibodies (1:1000). Antibody reactivity was visualised by ECL and quantified densitometrically, as described above.
Measurement of biotin-X-cadaverine incorporation into proteins serving as substrates for TG2
Cellular proteins acting as substrates for endogenous TG2-catalysed polyamine incorporation reactions were investigated as described by Singh et al. [31] . Biotincadaverine labelled proteins were enriched using CaptAvidin ™ -agarose sedimentation beads (Life Technologies, UK), subjected to SDS-PAGE and separated proteins stained with Coomassie blue.
Proteomic analysis of TG2 biotin-cadaverine labelled substrate proteins
Following pre-treatment with 1 mM biotin-X-cadaverine Hc92 cells were treated with CPA or adenosine and extracted as described above. The proteins labelled with biotin-X-cadaverine were purified using CaptAvidin ™ -agarose and biotin-cadaverine labelled proteins were processed for trypsin digestion (trypsin gold; Promega, Southampton, UK). 
Samples
Statistical analysis
All graphs and statistics (one-way ANOVA followed by Dunnet's multiple comparison test and two-way ANOVA for group comparison) were performed using GraphPad Prism ® software (GraphPad Software, Inc., USA). Results represent mean ± S.E.M. and p values <0.05 were considered statistically significant.
Results
Effect of A1 adenosine receptor activation on TG2-mediatedbiotincadaverine incorporation and protein cross-linking activity
Initial experiments investigated the effect of the selective A1 adenosine receptor agonist CPA and the endogenous agonist adenosine on TG2 activity in H9c2 cardiomyoblasts.
TGs can catalyse two types of cross-linking, namely (i) intra-, and/or inter-molecular covalent cross-links between protein-bound glutamine and protein-bound lysine residues, and (ii) cross-links between primary amines and protein-bound glutamine (both protein and polyamines links are transamidation).H9c2 cells were treated with CPA (1 µM) or adenosine (100 µM) for varying time periods and cell lysates subjected to the biotincadaverine amine-incorporation assay [25] . Both CPA and adenosine produced transient increases in TG2 catalysed biotin-cadaverine incorporation activity peaking at 10 min . It is important to note that CPA, adenosine and DPCPX had no significant effect on purified guinea pig liver TG2 activity (data not shown).
The effect of TG2 inhibitors on A1 adenosine receptor induced TG2 activity
To confirm that TG2 is the isoform linked to A1 adenosine receptor transglutaminase activity in H9c2 cardiomyocytes, two structurally different cell permeable TG2 specific inhibitors were tested; R283 (a small molecule; [34] ) and Z-DON (peptide-based; [35] ). activity similar inhibitory trends were observed but these were not always statistically significant. However, the A1 adenosine receptor antagonist DPCPX caused no noticeable effect on basal TG2 activity. In contrast, agonist activated levels of TG2 activity were consistently inhibited by either receptor antagonist or TG2 inhibitors. It is interesting to note that the levels of TG2 activity in the presence of CPA and R283 in particular are consistently lower than basal TG2 activity in the presence R283 alone. This is consistent with the possibility that CPA-activated TG2 is more amenable to inhibition by R283.
The effect of pertussis toxin and protein kinase inhibitors on A1 adenosine receptor-induced TG2 activity
Pre-treatment with pertussis toxin (Gi/o-protein blocker; 100 ng/ml for 16 h) completely 
Phosphorylation of TG2 following A1 adenosine receptor activation
The effect of A1 adenosine receptor activation on the phosphorylation status of TG2 was monitored via immunoprecipitation of TG2 followed by SDS-PAGE and Western blot analysis using anti-phosphoserine and anti-phosphothreonine antibodies. CPA (100 nM) 
Visualisation of in situ TG2 activity following CPA and adenosine treatment
Biotin-X-cadaverine, a cell penetrating primary amine, acts as the acyl-acceptor in intracellular TG2-mediated transamidating reactions and becomes incorporated into endogenous protein substrates of TG2, which can subsequently be visualised by reporters such FITC-and HRP-ExtrAvidin ® [37] . H9c2 cells were pre-incubated with 1 mM biotin-X-cadaverine for 6 h at 37°C prior to treatment with CPA or adenosine for 1, 5, 
Identification of biotin-cadaverine labelled protein substrates
To detect the protein substrates from CPA-and adenosine-treated cells, substrates in whole cell extracts were enriched using CaptAvidin ™ -agarose sedimentation beads, resolved by 4-15% SDS-PAGE, and visualised using Coomassie blue stain. Figure 15 shows that treatment for 10 min with CPA (100 nM) or adenosine (100 µM) increased the incorporation of biotin-X-cadaverine into several proteins of different molecular masses in H9c2 cells. As expected, the incorporation of biotin-X-cadaverine into TG2 (Table 1) .
The role of TG2 in A1 adenosine receptor-induced cell survival
Our previous studies have shown that TG2 is involved in cytoprotection triggered by PKA and PKC-dependent signalling pathways in H9c2 cells [27] . 
Discussion
In vitro modulation of TG2 by the A1 adenosine receptor
The A1 adenosine receptor agonist CPA and the endogenous agonist adenosine triggered a time-and concentration-dependent increase in TG2 activity in H9c2 cells. Adenosinemediated increases in TG2 activity were completely blocked by the A1 adenosine receptor antagonist DPCPX, suggesting involvement of the A1 adenosine receptor.
As previously indicated, very little is known regarding the regulation of TG2 enzymatic activity by GPCRs. Examples in the literature include muscarinic receptor-mediated increases in TG2 activity in SH-SY5Y cells [38] and 5-HT2A receptor mediated transamidation (TG-catalyzed) of the small G-protein Rac1 in the rat A1A1v cells [39] .
Zhang et al., [38] measured in situ TG2 activity (polyamine incorporation) triggered by the muscarinic agonist carbachol, whereas Dai et al., [39] reported TG2 catalysed incorporation of 5-hydroxytryptamine into Rac1. 5-HT2A receptor-mediated incorporation of 5-HT into the small GTPases RhoA and Rab4 was also observed in platelets [40] . It was suggested that 5-HT2A and muscarinic receptor-mediated release of Ca 2+ from intracellular Ca 2+ stores may be responsible for triggering TG transamidating activity [38, 40] . Hence, to our knowledge, the current study is the first demonstration of GPCR- 
Role of Ca 2+ in A1 adenosine receptor-mediated TG2 activation
Although coupled to Gi/o-proteins, the A1 adenosine receptor directly stimulates inositol phospholipid hydrolysis through G-protein β subunit-mediated activation of phospholipase C in DDT1MF-2 cells [42, 43] . In this study, CPA triggered an increase in An alternative mechanism for A1 adenosine receptor-induced Ca 2+ influx is via storeoperated Ca 2+ channels. Interestingly, the A1 adenosine receptor promotes receptoroperated Ca 2+ entry in cardiomyocytes via a phospholipase C and PKC-dependent pathway [48] . Although beyond the scope of the present study, it would be of interest to investigate the mechanism(s) underlying A1 adenosine receptor-induced Ca 2+ influx in H9c2 cells.
Role of protein kinases in A1 adenosine receptor-mediated TG2 activation
Although TG2 activity can be regulated by changes in intracellular [Ca 2+ ] there is growing evidence that TG activity can also be modulated by phosphorylation [7, 8] . The broad spectrum PKC inhibitor Ro 31-8220 and the MEK1/2 inhibitor PD 98059 completely blocked CPA and adenosine-induced TG2 activity, suggesting prominent roles for PKC and ERK1/2. Although ERK1/2 has been implicated in modulating the cross-linking activity of TG1 [8] there are no reports suggesting a role for this protein kinase in TG2 regulation.
It is interesting to note that ERK1/2 activation by the A1 adenosine receptor is sensitive to PKC inhibition in both neonatal rat cardiomyocytes [14] and H9c2 cells (data not shown) and, therefore, the role of PKC in TG2 activation maybe up-stream of ERK1/2. In view of the possible role of ERK1/2, we also determined whether A1 adenosine receptor- Indeed, our previous studies have shown that A1 adenosine receptor-induced ERK1/2 activation in DDT1MF-2 smooth muscle cells is dependent upon PI-3K activation [13] .
Whether, some of the upstream kinases associated with the A1 adenosine receptorinduced activation of JNK1/2 and ERK1/2 are also involved in modulating TG2 activity remains to be determined. Overall, it would seem that the A1 adenosine receptor regulates TG2 activity in H9c2 cells via a multi-protein kinase dependent pathway.
Although protein kinase inhibition and removal of extracellular Ca 2+ both inhibit CPAinduced TG2 activity, the relationship between the two is not yet known.
A1 adenosine receptor-induced phosphorylation of TG2
Given the apparent role of multiple serine/threonine kinases in the regulation of TG2 we investigated whether activation of the A1 adenosine receptor results in the phosphorylation of TG2. The data presented demonstrate that TG2 is phosphorylated in response to A1 adenosine receptor activation. To our knowledge, this represents the first report of enhanced TG2 phosphorylation in response to an exogenous stimulus. Previous studies have shown that TG2 is phosphorylated by PKA at Ser 215 and Ser 216 [52] and at an unknown site(s) by PTEN-induced putative kinase 1 (PINK1; [53] ). Phosphoproteomic based studies have identified numerous phosphorylation sites on Ser, Thr and Tyr residues in human and rat TG2 [54] [55] [56] [57] [58] [59] [60] . It would therefore be of value to identify the specific site(s) of TG2-associated serine and threonine phosphorylation triggered by the A1 adenosine receptor. It is interesting to note that PKA-mediated phosphorylation of TG2 has several consequences, including enhancement of protein-protein interactions and TG2 kinase activity [7, 52] , whereas PINK1-mediated phosphorylation of TG2 blocks its proteasomal degradation [53] . Thus, further studies are warranted in order to determine the functional consequence(s) of A1 adenosine receptor-induced TG2
phosphorylation. In view of the multiple protein kinases implicated in A1 adenosine receptor-induced TG2 activation, we investigated the influence of protein kinase inhibitors on TG2 phosphorylation. Although TG2 phosphorylation following A1 adenosine receptor activation was attenuated by PKC, ERK1/2 and JNK1/2 inhibitors, further studies are needed to confirm if these protein kinases directly catalyse the phosphorylation of TG2. It is notable that the p38 MAPK inhibitor SB203580 did not attenuate TG2 phosphorylation despite this kinase inhibitor blocking CPA-induced TG2 activity, suggesting that p38 MAPK modulates other targets involved in TG2 activation.
In situ modulation of TG2 activity and detection of TG2 protein substrates
Measurements of in situ TG2 activity following A1 adenosine receptor stimulation were comparable to CPA-and adenosine-induced amine incorporation activity observed in vitro. However, given the covalent nature of biotin-X-cadaverine incorporation into protein substrates, it was surprising to observe that in situ TG2 activity returned to basal levels after 40 min. Possible explanations for this include reversal of amine incorporation catalysed by TG [61] , that biotin-cadaverine labelled proteins were targeted for degradation or they were rapidly expelled from the cell. As we have previously reported the rapid expulsion of biotin-cadaverine labelled proteins from PMA-or forskolinstimulated H9c2 cells [27] , a similar mechanism may be responsible for the loss of biotinylated proteins following A1 adenosine receptor activation.
SWATH™-MS analysis identified 21 novel TG2 protein substrates and two previously identified substrates (Table 1) . Several of these proteins are associated with regulation of the cytoskeleton, transcription/translation, cell signaling and apoptosis, which supports the cytoprotective role for TG2 (see below). For example, hexokinase 1 (HK1) and acidic leucine-rich nuclear phosphoprotein 32 family member A (ANP32A) both exhibited in excess of 5-fold increases compared to the control. The former is a recognised as a mediator of cardioprotection via its interaction with mitochondrial voltage-dependent anion-selective channel protein 1 (VDAC1), which increased by over 2-fold in stimulated cells [62, 63] . Interestingly, VDAC1 was previously identified as a TG2 substrate in PMA-stimulated H9c2 cells [27] . It may be that TG2-mediated amine incorporation into HK1 and VDAC interferes with the ability of these proteins to interact with each other and modulate cardioprotection and/or cell survival [64] . It is also notable that ANP32A functions as an inhibitor of protein phosphatase 2A and thus may regulate ERK1/2 and PKC; therefore it is conceivable that its modification by TG2
interferes with signalling events associated with cell survival [65, 66] . As very little is currently known about the functional effects of TG2-mediated amine incorporation, further work to study the role of this phenomenon in TG2-induced cell survival would be warranted.
Role of TG2 in A1 adenosine receptor-induced cytoprotection
The A1 adenosine receptor mediates cell survival in several cell types including cardiomyocytes and neuronal cells [67, 68] . The current study shows for the first time that TG2 is involved cytoprotection triggered by the A1 adenosine receptor. TG2 is known to interact with or modulate a number of signalling pathways associated with cell survival against hypoxia and glucose deprivation-induced cell death, including hypoxia inducible factor 1β, NF-кB and PKB [69, 70] . It is also notable that several of the identified TG2 protein substrates are associated with cell survival/apoptosis. Further studies are required to determine the mechanism(s) associated with the role of TG2 in A1
adenosine receptor-induced cell survival.
In conclusion, our data has shown for the first time that TG2 activity is regulated by the A1 adenosine receptor in H9c2 cells. Furthermore, inhibitors of PKC, ERK1/2, p38 MAPK and JNK1/2 attenuated CPA-induced TG2 activation, suggesting a role for these kinases.
We have also shown that activation of the A1 adenosine receptor promotes TG2 phosphorylation via the aforementioned protein kinases and that TG2 plays a role in cytoprotection induced by CPA. Work to understand further the molecular mechanism(s)
underlying the activation of TG2 by the A1 adenosine receptor is currently underway. 
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H9c2 cells were pre-incubated with biotin-X-cadaverine prior to treatment with CPA (100 nM) and biotin-cadaverine labelled proteins were captured and analysed by SWATH MS.
*
Absolute fold change in CPA-treated samples versus control (n=4) were calculated using SCIEX OneOmics with parameters MLR weight > 0.15, confidence >60% algorithms used described by Lambert et al., [33] . Proposed novel TG2 targets not appearing in the TG2 substrate database [71] or identified by Yu et al. [72] 
